Al-Ola Abdallah

Hematology — University of Kansas Medical Center, United States

LeadR Profile

Al-Ola Abdallah University of Kansas Medical Center United States
1 161 ScienceLeadR Reputation 1161
Network Map

Hematology

Subspecialties: Oncology - Transplantation - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026

Source: PubMed

University of Kansas Medical Center

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 300

Citations

Citations: 2 138 1st author: 28 Last author: 29 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Masked divergence in cancer mortality following COVID-19 disruption.
mortality, neoplasms, covid-19, diagnosis, pandemics, therapeutics
Cancer Epidemiol20260
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.
cells, neoplasms, multiple myeloma, therapeutics, antibodies, bispecific
Curr Oncol20260
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
quality of life, multiple myeloma, therapeutics, hematologic diseases, digital health
Expert Rev Hematol20260
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.
neoplasms, chromosome aberrations, transplants, therapeutics, cytogenetics
Curr Oncol20260
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis.
proteasome inhibitors, microscopy, electron, scanning transmission, neoplasms, multiple chronic conditions, maintenance, aged, multiple myeloma, therapeutics, cytogenetics
Curr Oncol20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
Phase 2 2
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Active not recruiting 3
Recruiting 2
Completed 1
Terminated 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016 — cells, microscopy, electron, scanning transmission, multiple chronic conditions, stem cells, maintenance, multiple myeloma, lenalidomide, transplants, therapeutics, cell transplantation, stem cell transplantation, transplantation
Phase 3Active not recruiting2023
A Study to Evaluate Mezigdomide Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085 — dexamethasone, bortezomib, multiple myeloma, calcium, calcium dobesilate
Phase 3Recruiting2022

LeadR Networks

Main global connection map